Could chickpea flour bread tame blood sugar spikes?
NCT ID NCT07716059
First seen Jul 21, 2026 · Last updated Aug 21, 2026 · Updated 2 times
Summary
This study looks at whether replacing some wheat flour with chickpea flour in bread can lower blood sugar rises after eating. Healthy adults and people with type 2 diabetes will eat bread made with finely or coarsely ground chickpea flour, and their blood sugar will be tracked continuously. The goal is to see if the legume flour, especially the coarser grind, leads to a gentler glucose response compared to regular white bread.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- bread with 30% chickpea flour (finely milled or coarse)
- What this could lead to
- If it works, this could point toward a simple dietary swap—using legume flour in bread—to help manage blood sugar spikes after meals.
- What could go wrong
- This is a small, early-stage trial with only 35 participants, so results may not apply to everyone. The effect on long-term diabetes control is not tested here.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 35 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2025
- Expected to finish
-
Nov 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Cohort Healthy Participants Inclusion Criteria: * Age: Adults aged 18-35 years. * Health Status: Healthy individuals with no diagnosed chronic diseases, including diabetes, cardiovascular disease, or gastrointestinal disorders. * Body Mass Index (BMI): 18.5-27 kg/m² (normal to overweight range). * Fasting Glucose: Normal fasting plasma glucose (\<100 mg/dL or \<5.6 mmol/L). * No regular use of medications known to affect glucose metabolism (e.g., insulin, metformin, corticosteroids). * Ability and willingness to comply with study procedures, including continuous glucose monitoring and standardized test meals. * Informed Consent: Ability to understand and provide written informed consent. Exclusion Criteria: * Diagnosed chronic diseases: Diabetes (type 1 or type 2), cardiovascular disease, kidney or liver disease, gastrointestinal disorders (e.g., celiac disease, inflammatory bowel disease). * Abnormal glucose metabolism: Fasting plasma glucose ≥100 mg/dL (≥5.6 mmol/L) or HbA1c ≥5.7%. * Medication use: Regular use of medications that affect glucose metabolism, insulin sensitivity, or digestion (e.g., metformin, corticosteroids, GLP-1 analogs). * Allergies or intolerances: Allergy or intolerance to wheat, chickpeas, gluten, or other ingredients used in the study foods. * Pregnancy or lactation: Women who are pregnant, breastfeeding, or planning pregnancy during the study period. * Recent major weight change: Significant weight loss or gain (\>5% body weight) in the past 3 months. * Extreme physical activity: Competitive athletes or individuals engaging in extreme exercise regimens that could influence glucose metabolism. * Inability to comply: Individuals unable or unwilling to follow study procedures, including continuous glucose monitoring and standardized test meals. Cohort 2: Participants with Type 2 Diabetes Mellitus Men and women aged 40-75 years. Body mass index (BMI) \< 31 kg/m². Fasting plasma glucose \> 125 mg/dL. HbA1c \< 8.5%. Diagnosis of type 2 diabetes mellitus (T2DM) for at least 1 year before enrolment. Stable treatment with hypoglycaemic, lipid-lowering, and/or antihypertensive medications for at least 3 months prior to enrolment. Most participants will be recruited from the Diabetes Clinic of the 1st Propaedeutic Department of Internal Medicine, Laiko General Hospital. Exclusion criteria Endocrine, cardiovascular, pulmonary, renal, or gastrointestinal disorders that could affect study outcomes. Sensitivity, intolerance, or allergy to any ingredients of the study breads. Pregnancy or breastfeeding. Eating disorders. Use of medications or dietary supplements considered incompatible with the study protocol.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
1st Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 15772 Athens, Greece
RECRUITINGAthens, Attica, Greece
-
Harokopio University
RECRUITINGAthens, Attica, 17676, Greece
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Cost-Effectiveness and implementation of integrated Diabetes-Oral health care in oman: a health belief Model-Based intervention to enhance clinical, behavioral, and exploratory oral microbiome in health system outcomes in type 2 diabetes
- Fibrinogen to albumin ratio (FAR) as a risk factor for type 2 diabetic Nephropathy(DN)
- A digital coach for hunger: can an app retrain appetite to improve diabetes control?
- Can a numbing gel on the feet beat a daily pill for diabetic nerve pain?
- Can a crocosmia bulb compound tame type 2 diabetes?
- Can a wearable sensor improve blood sugar control in hospitals?